There are currently 195 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
NCT01408225
Recruiting
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma
Register for Updates
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
NCT05831358
Recruiting
This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pil... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/26/2024
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Register for Updates
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
NCT06087653
Recruiting
Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives To assess the immunologic activity of natural killer (NK) cells and T cells for innate and humoral immunity. To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations. To determine pharmacodyna... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Gabrail Cancer & Research Center, Canton, Ohio
Conditions: Multiple Myeloma
Register for Updates
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511
Recruiting
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of California Los Angeles (UCLA), Los Angeles, California +27 locations
Conditions: Multiple Myeloma
Register for Updates
Tissue Collection for Studies of Lymph Cancer
NCT01676805
Recruiting
Background: - Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue. Objectives: - To collec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis, Leukemia-Lymphoma, Adult T-Cell
Register for Updates
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Recruiting
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
02/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma
Register for Updates
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
NCT06169215
Recruiting
This phase II trial compares the combination of selinexor, daratumumab, velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-risk newly diagnosed multiple myeloma. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Daratumumab is i... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/20/2025
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California +26 locations
Conditions: Multiple Myeloma
Register for Updates
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401
Recruiting
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
02/20/2025
Locations: Thomas Hospital, Fairhope, Alabama +139 locations
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Metastatic Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Multiple Myeloma, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Register for Updates
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
NCT06142396
Recruiting
The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients. The primary questions this study aims to answer are: 1. To evaluate the very good partia... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2025
Locations: Georgia Cancer Center-Augusta University, Augusta, Georgia
Conditions: Multiple Myeloma, Renal Failure
Register for Updates
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
NCT05393804
Recruiting
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma
Register for Updates
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
NCT06559709
Recruiting
This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant. An autologous hematopoietic cell transplant is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Loss of microbial diversity within the intestinal tract has been associated with poor outcomes for patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Multiple Myeloma
Register for Updates
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Scripps Clinic Torrey Pines, La Jolla, California +38 locations
Conditions: Multiple Myeloma
Register for Updates